Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Evercore ISI upgraded shares of TXNM Energy (NYSE:TXNM – Free Report) from an in-line rating to an outperform rating in a ...

Evercore ISI analyst Kirk Materne maintained a Hold rating on Tyler Technologies (TYL – Research Report) yesterday and set a price target of ...

Walgreens Chief Executive Officer Tim Wentworth reiterated on an earnings call last month that the company plans to divest ...

Five-star-rated analyst Mark Mahaney at Evercore ISI has downgraded his rating from Buy to Hold on The Trade Desk (TTD) after ...

Riot Platforms is expanding into AI and high-performance computing partnerships while adding three new board members with ...

The assets are SBB doo Belgrade, NetTV Plus business and its sports broadcasting rights for the Western Balkans.